| Cat.No. | Name | Information |
|---|---|---|
| M9199 | Avacopan | Avacopan (CCX168) is a first-in-class, potent, selective and orally available complement 5a receptor (C5aR1 or CD88) antagonist with an IC50 of 0.1 nM. |
| M29607 | JR14a | JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation. |
| M24911 | Pozelimab | Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases. |
| M21383 | Ravulizumab | Ravulizumab, a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, is being evaluated as an investigational approach in COVID-19-associated severe pneumonia, acute lung injury and acute respiratory distress syndrome. |
| M20998 | PMX-53 | PMX-53 is a potent CD88 (C5aR) antagonist with an IC50 of 20 nM, it inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. |
| M14076 | Iptacopan | Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 value of 10 nM. |
| M14075 | Compstatin TFA | Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. |
| M14072 | AMY-101 TFA | AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). |
| M11438 | Zilucoplan | Zilucoplan is a 15 amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor that specifically targets C5, a component of the terminal complement activation pathway, thereby preventing the cleavage of C5 by C5 converting enzyme into complement components C5a and C5b, and thus preventing the downstream assembly and activity of the membrane attack complex (MAC). Can be used in studies related to immune-mediated necrotizing myopathy (IMNM) and generalized myasthenia gravis (gMG). |
| M10317 | LNP023 hydrochloride (Iptacopan HCl) | Iptacopan (LNP023) hydrochloride is a first-in-class orally bioavailable, highly potent and selective complement factor B inhibitor with an IC50 value of 10 nM. |
| M10145 | Danicopan (ALXN2040) | Danicopan (ALXN2040, ACH-4471, ACH-0144471) is a first-in-class, potent, selective, orally active inhibitor of complement factor D with a Kd value of 0.54 nM for human Factor D. Danicopan can Selectively inhibits key complement factor D in the alternative pathway, blocking C3 convertase production and inhibiting alternative pathway activity. It also prevents the deposition of C3b fragments on blood erythrocytes and inhibits erythrocyte catabolism and extravascular hemolysis. |
| M10140 | TLQP-21 TFA | TLQP-21 is a VGF-derived peptide, which protects cerebellar granule cells (CGCs) from serum and potassium deprivation-induced apoptosis and increases energy expenditure and prevents early phase diet-induced diabetes. |
| M10114 | PMX 205 Trifluoroacetate | PMX 205 Trifluoroacetate is a potent complement antagonist of C5a (C5aR; CD88) receptor. |
| M10084 | AMY-101 acetate | AMY-101 acetate is a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM). |
| M8983 | Compstatin | Compstatinis is a 13-residue cyclic peptide, binds to complement component C3 and inhibits complement activation with IC50 of 12 μM. Compstatin exhibits exclusive specificity for primate C3s and does not bind either to C3s from lower mammalian species or to two structural homologs of C3, human C4 and C5. |
| M8470 | SB290157 trifluoroacetate salt | SB290157 is a selective antagonist of complement anaphylatoxin C3a receptor, a 74 amino acid proinflammatory peptide that is a potent chemotaxin for eosinophils, macrophages and mast cells. |
| M1598 | Eculizumab | Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species. |
| M54558 | P014 | P014 is a C5 antibody/CFH fragment fusion protein that can be used in studies related to paroxysmal sleep hemoglobinuria (PNH) and thrombotic microangiopathy (TMA). |
| M54080 | POT-4 | POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. |
| M52862 | TLQP-21 | TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
